First-in-human trial of multikinase VEGF inhibitor regorafenib and anti-EGFR antibody cetuximab in advanced cancer patients

BACKGROUND. The combination of multikinase VEGF inhibitor regorafenib and anti-EGFR antibody cetuximab overcomes intrinsic and acquired resistance in both EGFR-sensitive and EGFR-resistant preclinical models of colorectal cancer (CRC). METHODS. Utilizing a standard 3+3 design, a phase I study was de...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JCI Insight
Main Authors: Subbiah, Vivek, Khawaja, Muhammad Rizwan, Hong, David S., Amini, Behrang, Yungfang, Jiang, Liu, Hui, Johnson, Adrienne, Schrock, Alexa B., Ali, Siraj M., Sun, James X., Fabrizio, David, Piha-Paul, Sarina, Fu, Siqing, Tsimberidou, Apostolia M., Naing, Aung, Janku, Filip, Karp, Daniel D., Overman, Michael, Eng, Cathy, Kopetz, Scott, Meric-Bernstam, Funda, Falchook, Gerald S.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Clinical Investigation 2017
Assuntos:
Clinical Medicine
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5396533/
https://ncbi.nlm.nih.gov/pubmed/28422758
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.90380
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados